Semaglutide improved multiple measures of disordered eating and body image in adults with obesity compared with placebo, according to a secondary analysis presented at ObesityWeek 2026 and published in the International Journal of Eating Disorders.
The analysis drew on a 60‑week trial of 120 adults with obesity who were randomly assigned to semaglutide 2.4 mg or placebo alongside structured lifestyle counseling. At baseline, 6.9% of the semaglutide group and 12.5% of the placebo group met criteria for binge‑eating disorder (BED), while 22.2% and 31.3%, respectively, reported any binge episodes in the prior 12 weeks, Medscape reported.
Participants receiving semaglutide showed significantly larger reductions in the Eating Disorder Inventory global score, loss‑of‑control eating, uncontrolled eating and body‑dissatisfaction scores at weeks 20, 40 and 60. Among participants who entered the study with binge eating episodes or full or subthreshold binge-eating disorder, those receiving semaglutide were more likely to achieve remission and abstinence from binge eating behaviors.
Of the eight semaglutide‑treated participants with full or subthreshold BED at baseline, none met BED criteria at weeks 20 or 40 and 88% remained in remission at week 60, compared with 75% remission in the placebo group, according to Medscape.
“Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients,” said Jena Tronieri, PhD, senior research investigator at Penn’s Center for Weight and Eating Disorders and senior author of the study, Newswise reported.
Lead investigator Kelly Costello Allison, PhD, director of Penn’s Center for Weight and Eating Disorders, said the data should reassure clinicians but also underscore the need for vigilance.
“Despite concerns that large, rapid weight losses could precipitate disordered eating and psychosocial complications, semaglutide, relative to placebo, showed larger improvements in several measures of disordered eating and body image concern. Onset of new eating disorder pathology was rare, as was worsening of existing pathology,” she said during her ObesityWeek presentation.
Allison added that clinicians “should feel comfortable asking people how their eating is going in a broad open way…people with restrictive eating disorders sometimes want to keep those behaviors to themselves but I think providers do need to be aware that this could be an issue.” She co‑authored a recent consensus document recommending universal screening for current or prior eating disorders before initiating any GLP‑1 receptor agonist.
The trial had higher dropout in the placebo arm — 56.3% completed questionnaires at week 60 versus 84.7% in the semaglutide arm — a pattern Allison attributed to participants suspecting they were on placebo given the medication’s pronounced weight‑loss effects. The study was funded in part by a Novo Nordisk NNI Investigator Sponsored Studies Program grant, Newswise noted.
- Normandy ARS Launches €18M Call for Hospital Heat-Protection Projects by Summer 2028
- Electronic Comb Regrows 97.85% of Hair in Mice, Study Finds
- Toward a Healthier Future Through Obesity Prevention and Care The JAMA Summit Report on Obesity (newsylist.com)
- Colorado Women’s Basketball Beats New Mexico, Improves to 5-0 (news-usa.today)